Rita Banzi

Mario Negri Institute for pharmacological research

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Ugo Lucca

Istituto di Ricerche Farmacologiche Mario Negri

ITALY

View details

Enrico Glaab

LUXEMBOURG

View details

Montserrat Carmona

Profesora

SPAIN

View details

Daniel Paris

UNITED STATES

View details

Iñaki Imaz-Iglesia

SPAIN

View details

Giuseppe Saglio

PROFESSOR

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rita Banzi

Research Interests

Explore related searches

Contact this professor

Articles (10)

Study designs for clinical trials applied to personalised medicine: a scoping review

High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries

Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis

Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD

Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: Data from NILVAD

Assessment of a demonstrator repository for individual clinical trial data built upon DSpace

Clinical evidence supporting the marketing authorization of biosimilars in Europe

Feasibility and efficacy of home monitoring for patients with suspected or confirmed COVID-19,Fattibilità ed efficacia di un modello di monitoraggio domiciliare avanzato dei pazienti affetti da CoViD-19 o sospetti

Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval

Collaborators (6)

Ugo Lucca

Enrico Glaab

Montserrat Carmona

Daniel Paris

Iñaki Imaz-Iglesia

Giuseppe Saglio

Make your next move.